Pharma News: Label Change to Bydureon, Inspire Trial Fails Monday, March 15, 12:41 PM ET
The Food and Drug Administration is demanding clarifications on the labeling and manufacturing process for Bydureon, a new drug candidate of Amylin Pharmaceuticals (AMLN), Eli Lilly (LLY) and Alkermes (ALKS).
The FDA would like changes made to clarify the product labeling and asked questions about the drug’s manufacturing process.
Bydureon is a once weekly form of the Type II diabetes drug Byetta, which already has annual sales of $700 million.
The drug has been developed by Amylin and Lilly, and uses controlled release technology from Alkermes.
The companies will respond to the FDA’s requests within a few weeks.
Amylin shares are trading over 8 percent Monday, while Lilly shares are trading about flat.
Also in the pharma industry this morning, Inspire Pharmaceuticals (ISPH) said today two Phase II clinical trials of its blepharitis drug Azasite failed to meet primary endpoints. Blepharitis is inflammation of the eyelids.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.
Free Email Alerts By Stock:
Monday 10/12 Insider Buying Report: NMCO, CRNC 
Monday 10/12 Insider Buying Report: BPRE, MWA 
Friday 10/9 Insider Buying Report: FEAM, NRXS 
Nasdaq 100 Movers: SNDK, HONIV 
S&P 500 Movers: SNDK, HONIV 
Dow Movers: CSCO, HONIV 
Dow Analyst Moves: AXP 
S&P 500 Analyst Moves: RCL 
S&P 500 Analyst Moves: DXCM
Monday Sector Laggards: Semiconductors, Computer Peripherals 
Monday Sector Leaders: Hospital & Medical Practitioners, Oil & Gas Exploration & Production Stocks 
Friday Sector Laggards: Television & Radio, General Contractors & Builders 
Monday's ETF with Unusual Volume: PBDC 
Monday's ETF Movers: IHI, REMX 
TSLL, SUIL: Big ETF Outflows 
Daily Dividend Report: AEE,R,LMT,COKE,VMC
Daily Dividend Report: RPM,CSX,ZTS,EPD,NWN
Daily Dividend Report: SBUX,CF,CARR,AGNC,DHC